Solid Biosciences is a life science company focused on developing a portfolio of neuromuscular and cardiac programs, including SGT-003, a gene therapy candidate, for the treatment of Duchenne muscular dystrophy; AVB-202-TT, a gene therapy program for the treatment of Friedreich's ataxia; AVB-401, a gene therapy program for the treatment of BCL-2-associated athanogene 3-mediated dilated cardiomyopathy (DCM); and additional assets for the treatment of undisclosed cardiac diseases. Co. also has two pipeline programs, AVB-501 for DCM and AVB-601 for hypertrophic, that are both in preclinical development to treat undisclosed cardiac indications. The SLDB average annual return since 2018 is shown above.
The Average Annual Return on the SLDB average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether SLDB average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the SLDB average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|